TRAIL and cancer immunotherapy: Take a walk on the short side.

TRAIL and cancer immunotherapy: Take a walk on the short side. Clin Cancer Res. 2020 Aug 26;: Authors: De Miguel D, Pardo J Abstract Recent work shows that TRAILshort, a membrane-bound short form of TRAIL, is expressed by human cancer cells and protects them from TRAIL-induced cell death. A monoclonal antibody that selectively targets TRAILshort enhances cancer susceptibility to TRAIL and increases the efficacy of autologous CD8+T cells in ex vivo primary tumours. PMID: 32847932 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research